Screening test of Fabry disease by pain in childre
Phase 1
Recruiting
- Conditions
- Fabry disease
- Registration Number
- JPRN-UMIN000015625
- Lead Sponsor
- Department of Pediatrics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Not to be able to obtain the informed coscent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To detect the patients with Fabry disease in their early stages.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pain as a biomarker for Fabry disease in JPRN-UMIN000015625 pediatric screening?
How does pain-based screening in JPRN-UMIN000015625 compare to alpha-galactosidase A activity assays for early Fabry disease detection in children?
Which biomarkers are evaluated in JPRN-UMIN000015625 to predict Fabry disease risk in pediatric populations with chronic pain?
What adverse events are associated with pain assessment protocols in JPRN-UMIN000015625's Fabry disease screening for children?
How does early detection via pain screening in JPRN-UMIN000015625 influence enzyme replacement therapy efficacy in pediatric Fabry disease patients?